Gastric Cancer News and Research

RSS

Study: Loss of tight junction barrier protein results in gastric cancer development

Tight junctions are multi-protein complexes that serve as barriers in epithelial tissues such as the skin or lining of the gut. Loss of a specific tight junction barrier protein, claudin 18, occurs in the majority of gastric cancer patients and is correlated with poor prognosis in patients with advanced gastric cancer.

13 Dec 2018

New approach turns B cells into factories that secrete sacs containing microRNAs

Cancer immunotherapy -- efforts to better arm a patient's own immune system to attack tumors -- has shown great potential for treating some cancers. Yet immunotherapy doesn't work for everyone, and some types of treatment can cause serious side effects.

5 Dec 2018

Researchers discover molecular basis for therapeutic actions of an African folk medicine

Researchers in the Department of Physiology & Biophysics at the University of California, Irvine School of Medicine have discovered the molecular basis for therapeutic actions of an African folk medicine used to treat a variety of illnesses and disorders including diabetes, pain, headaches, paralysis and epilepsy.

15 Nov 2018

New anti-HER2 drug shows promising anti-tumor activity in gullet, stomach and bowel cancers

An antibody that binds simultaneously to two distinct regions of the HER2 receptor to block the growth of cancer cells has shown promising signs of anti-tumor activity in a number of cancers including those of the gullet (esophagus), stomach and bowel.

14 Nov 2018

Researchers uncover link between RNA abnormalities and multiple myeloma progression

Multiple myeloma is the second most common type of blood cancer where cancer cells accumulate in the bone marrow, crowding out healthy blood cells.

1 Nov 2018

$Phase III LONSURF study shows progression-free survival in patients with refractory metastatic gastric cancer$

Phase III LONSURF study shows progression-free survival in patients with refractory metastatic gastric cancer

Servier and Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), jointly announced today clinical data from the pivotal Phase III TAS-102 Gastric Study (TAGS) evaluating LONSURF® (trifluridine/tipiracil, TAS-102) versus placebo and best supportive care in patients with heavily pre-treated metastatic gastric cancer who have progressed or are intolerant to previous lines of therapy.

22 Oct 2018

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck, known as MSD outside the United States and Canada, today announced the first presentation of preliminary data from a Phase 1 clinical trial evaluating MK-1454, an investigational STING (stimulator of interferon genes) agonist, as monotherapy and in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, in patients with advanced solid tumors or lymphomas.

22 Oct 2018

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Merck, known as MSD outside the United States and Canada, today announced the first presentation of results from an interim analysis of KEYNOTE-057, a Phase 2 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, for previously treated patients with high-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ or CIS plus papillary disease (Cohort A).

22 Oct 2018

Study finds differences in side-effects experienced by male and female OG cancer patients

Men and women may need to be treated differently - at least when it comes to some types of cancer. In an analysis to be presented at the ESMO 2018 Congress in Munich, data was pooled from four UK randomized controlled clinical trials of first line chemotherapy in oesophagogastric cancer, finding significant differences in a number of important side-effects experienced by male and female patients.

19 Oct 2018

World Stomach Day: International initiative to raise awareness and support for a vital organ

Tuesday, 2 October 2018 marks the first ever World Stomach Day, an international initiative to raise awareness and support for one of our most vital organs.

3 Oct 2018

Study aims to investigate risk factors for PPCs in surgical patients with gastric cancer

As one of the most common malignant tumors, gastric cancer occupies the second leading cause of cancer-related deaths worldwide with an increasing trend.

18 Sep 2018

Study identifies potential guidance to treat gastric cancer patients

Researchers from Wake Forest Baptist Medical Center and Tianjin Medical University Cancer Institute and Hospital have discovered that gastric cancer tissue samples bearing mutation of a specific gene, MUC16, too are associated with higher tumor mutation loads.

14 Aug 2018

Scientists find new molecular biomarker for gastric cancer

Although immunotherapy is seen as a very promising treatment for cancer, currently only 20 to 30 percent of patients respond positively. Being able to identify the people most likely to benefit from the costly therapy is a Holy Grail for oncologists.

9 Aug 2018

CNDA approves KEYTRUDA for treatment of advanced melanoma

Merck, known as MSD outside the United States and Canada, today announced that KEYTRUDA, Merck's anti-PD-1 therapy, has been approved by the China National Drug Administration for the treatment of adult patients with unresectable or metastatic melanoma following failure of one prior line of therapy.

26 Jul 2018

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Merck, known as MSD outside the United States and Canada, announced today that the pivotal Phase 3 KEYNOTE-048 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma, met a primary endpoint of overall survival as monotherapy in patients whose tumors expressed PD-L1.

25 Jul 2018

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has accepted for standard review a new supplemental Biologics License Application for KEYTRUDA, Merck's anti-PD-1 therapy, as adjuvant therapy in the treatment of patients with resected, high-risk stage III melanoma and granted a Prescription Drug User Fee Act, or target action, date of February 16, 2019.

25 Jun 2018

UC Riverside researcher receives grants to advance cancer, ALS research

Maurizio Pellecchia, who holds the Daniel Hays Chair in Cancer Research at the University of California, Riverside, has received two grants to continue his research aimed at finding therapeutics for cancer, amyotrophic lateral sclerosis, and other neurodegenerative diseases.

21 Jun 2018

Between death and deportation

This is the beginning of a plea written by a 13-year-old girl to the Department of Homeland Security. The goal: to get her mother the insurance coverage she would need to enter a clinical trial.

18 May 2018

Scientists develop integrated system for early diagnosis of diseases using wearable monitors

Researchers from the Wolfson Faculty of Chemical Engineering at the Technion-Israel Institute of Technology have developed an integrated system for early diagnosis of diseases using wearable monitors.

16 May 2018

Preclinical study suggests ARID1a mutations may help predict immunotherapy success

Functional loss of ARID1a, a frequently mutated tumor suppressor gene, causes deficiencies in normal DNA repair and may sensitize tumors to immune checkpoint blockade therapies, according to researchers from The University of Texas MD Anderson Cancer Center.

8 May 2018

Gastric Cancer News and Research

Study: Loss of tight junction barrier protein results in gastric cancer development

New approach turns B cells into factories that secrete sacs containing microRNAs

Researchers discover molecular basis for therapeutic actions of an African folk medicine

New anti-HER2 drug shows promising anti-tumor activity in gullet, stomach and bowel cancers

Researchers uncover link between RNA abnormalities and multiple myeloma progression

Phase III LONSURF study shows progression-free survival in patients with refractory metastatic gastric cancer

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Study finds differences in side-effects experienced by male and female OG cancer patients

World Stomach Day: International initiative to raise awareness and support for a vital organ

Study aims to investigate risk factors for PPCs in surgical patients with gastric cancer

Study identifies potential guidance to treat gastric cancer patients

Scientists find new molecular biomarker for gastric cancer

CNDA approves KEYTRUDA for treatment of advanced melanoma

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

UC Riverside researcher receives grants to advance cancer, ALS research

Between death and deportation

Scientists develop integrated system for early diagnosis of diseases using wearable monitors

Preclinical study suggests ARID1a mutations may help predict immunotherapy success

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Lab Matters host Harriet Gould on building a more connected lab community

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

Latest News